Go Pro
→ Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press) (Ad)tc pixel Free TAK Stock Alerts

Takeda Pharmaceutical (TAK) Financials

Takeda Pharmaceutical logo
$15.92 +0.27 (+1.69%)
Closing price 06/26/2026 03:59 PM Eastern
Extended Trading
$15.92 +0.01 (+0.06%)
As of 06/26/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Takeda Pharmaceutical

Annual Income Statements for Takeda Pharmaceutical

This table shows Takeda Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 1,032 1,758 1,214 413 3,399 1,894 2,388 953 720 -958
Consolidated Net Income / (Loss)		 1,037 1,757 1,213 413 3,401 1,895 2,388 954 721 -956
Net Income / (Loss) Continuing Operations		 1,037 1,757 1,213 413 3,401 1,895 2,388 954 721 -956
Total Pre-Tax Income 		1,287 2,044 1,146 -567 3,311 2,492 2,826 349 1,168 -895
Total Operating Income		 1,399 2,275 2,135 937 4,604 3,795 3,695 1,416 2,285 39
Total Gross Profit		 10,534 11,992 12,982 20,543 19,919 20,275 20,967 18,761 20,022 18,444
Total Revenue		 15,550 16,658 18,835 30,712 28,908 29,389 30,339 28,196 30,564 28,324
Operating Revenue		 15,550 16,658 18,835 30,712 28,908 29,389 30,339 28,196 30,564 28,324
Total Cost of Revenue		 5,016 4,666 5,853 10,169 8,988 9,114 9,372 9,434 10,542 9,879
Operating Cost of Revenue		 5,016 4,666 5,853 10,169 8,988 9,114 9,372 9,434 10,542 9,879
Total Operating Expenses		 9,134 9,717 10,847 19,606 15,316 16,480 17,272 17,346 17,737 18,405
Selling, General & Admin Expense		 5,558 5,910 6,445 9,002 7,916 7,299 7,513 6,969 7,370 6,816
Marketing Expense		 1,407 1,149 1,604 4,250 3,814 3,894 4,086 4,312 4,291 3,983
Research & Development Expense		 2,804 3,062 3,308 4,595 4,121 4,332 4,771 4,827 4,871 4,249
Other Operating Expenses / (Income)		 -1,289 -1,594 -1,436 -562 -2,875 -355 -192 -128 -175 -156
Impairment Charge		 654 1,191 926 2,321 2,340 1,310 1,094 1,366 1,379 3,514
Total Other Income / (Expense), net		 -112 -231 -989 -1,504 -1,293 -1,303 -869 -1,067 -1,117 -934
Interest Expense		 209 300 748 1,540 2,248 1,372 1,278 1,454 1,401 2,248
Interest & Investment Income		 110 372 151 260 954 195 474 344 311 1,327
Other Income / (Expense), net		 -14 -303 -392 -224 0.69 -127 -65 43 -27 -14
Income Tax Expense		 250 287 -67 -980 -90 596 437 -604 447 61
Net Income / (Loss) Attributable to Noncontrolling Interest		 -5.14 1.67 1.01 -0.46 -1.50 -0.88 -0.16 -0.86 -1.43 -1.66
Basic Earnings per Share		 $147.15 $239.35 $140.61 $28.41 $240.72 $1.21 $1.54 $0.61 $0.46 ($0.61)
Weighted Average Basic Shares Outstanding		 - - 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B 1.72B
Diluted Earnings per Share		 $146.26 $237.56 $139.82 $28.25 $238.96 $1.20 $1.52 $0.60 $0.45 ($0.61)
Weighted Average Diluted Shares Outstanding		 - - 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B 1.72B
Weighted Average Basic & Diluted Shares Outstanding		 - - 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B 1.72B

Quarterly Income Statements for Takeda Pharmaceutical

No quarterly income statements for Takeda Pharmaceutical are available.

Annual Cash Flow Statements for Takeda Pharmaceutical

This table details how cash moves in and out of Takeda Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -938 -392 3,943 -404 2,858 -1,196 -2,554 -674 -409 1,103
Net Cash From Operating Activities		 2,346 3,555 -2,950 6,250 9,139 9,248 7,361 4,737 7,053 6,547
Net Cash From Continuing Operating Activities		 2,346 3,555 2,950 6,182 11,218 9,313 7,412 5,097 7,081 5,846
Net Income / (Loss) Continuing Operations		 1,037 1,757 1,213 413 3,401 1,895 2,388 954 721 -956
Consolidated Net Income / (Loss)		 1,037 1,757 1,213 413 3,401 1,895 2,388 954 721 -956
Depreciation Expense		 1,539 1,714 2,225 5,446 5,059 4,802 5,005 4,814 5,079 4,533
Non-Cash Adjustments To Reconcile Net Income		 -241 44 -36 2,325 1,837 2,023 1,842 2,963 2,340 2,333
Changes in Operating Assets and Liabilities, net		 11 41 -451 -2,003 922 593 -1,823 -3,633 -1,060 -64
Net Cash From Investing Activities		 -5,887 -878 -25,467 2,726 3,557 -1,631 -4,573 -3,067 -2,449 -2,320
Net Cash From Continuing Investing Activities		 -5,887 -878 -25,465 2,726 3,557 -1,631 -4,573 -2,847 -2,522 -2,289
Purchase of Property, Plant & Equipment		 -1,006 -1,207 -1,204 -2,032 -2,138 -1,532 -4,774 -3,179 -2,320 -2,583
Purchase of Investments		 -109 -834 -154 -70 -114 -69 -76 -45 -651 -100
Sale of Property, Plant & Equipment		 24 28 455 117 420 15 7.25 57 0.52 41
Divestitures		 578 800 765 4,307 4,795 232 60 132 137 209
Sale and/or Maturity of Investments		 98 478 665 581 688 191 233 214 318 161
Other Investing Activities, net		 -183 122 577 -132 -93 -60 -23 -26 -7.41 -17
Net Cash From Financing Activities		 2,603 -3,069 26,460 -9,380 -9,839 -8,813 -5,342 -2,344 -5,013 -3,123
Net Cash From Continuing Financing Activities		 2,603 -3,069 26,460 -9,380 -9,839 -8,813 -5,342 -2,741 -5,326 -3,123
Repayment of Debt		 -1,820 -5,221 2,794 -11,286 -17,604 -7,889 -3,530 -1,315 -9,685 -4,440
Repurchase of Common Equity		 -208 -176 0.00 -35 -334 -638 -203 -15 -346 -324
Payment of Dividends		 -1,272 -1,335 -1,284 -2,637 -2,562 -2,336 -2,105 -1,899 -2,018 -1,961
Issuance of Debt		 5,990 3,702 25,110 4,630 10,663 2,053 565 661 6,834 3,684
Other Financing Activities, net		 -88 -38 -150 -52 -1.55 -3.17 -69 -173 -111 -82

Quarterly Cash Flow Statements for Takeda Pharmaceutical

No quarterly cash flow statements for Takeda Pharmaceutical are available.

Annual Balance Sheets for Takeda Pharmaceutical

This table presents Takeda Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets		 38,636 123,873 119,640 116,726 108,515 105,143 99,913 95,052 97,508
Total Current Assets		 10,150 26,880 23,044 24,524 21,357 18,064 16,920 16,819 19,427
Cash & Equivalents		 2,771 6,305 5,950 8,735 6,997 4,019 3,027 2,569 3,741
Accounts Receivable		 3,954 6,663 7,064 7,079 5,737 4,892 4,420 4,733 5,307
Inventories, net		 2,041 12,653 8,556 7,002 7,025 7,546 8,062 8,121 8,779
Current Deferred & Refundable Income Taxes		 80 65 260 268 228 243 193 105 201
Other Current Assets		 1,304 1,194 1,213 1,441 1,370 1,364 1,217 1,201 1,286
Plant, Property, & Equipment, net		 5,051 11,962 12,937 13,143 13,034 12,740 13,158 13,130 13,331
Total Noncurrent Assets		 23,435 85,030 83,660 79,058 74,124 74,339 69,835 65,103 64,750
Long-Term Investments		 1,016 972 1,002 3,149 2,718 2,854 2,848 2,414 2,821
Goodwill		 9,684 38,082 37,443 36,466 36,296 36,088 35,776 35,520 36,516
Intangible Assets		 9,543 42,670 38,925 35,338 31,444 32,163 28,268 24,227 21,495
Noncurrent Deferred & Refundable Income Taxes		 611 799 2,875 3,198 2,985 2,757 2,605 2,473 3,434
Other Noncurrent Operating Assets		 2,582 2,508 3,415 907 680 477 339 469 484
Total Liabilities & Shareholders' Equity		 38,636 123,873 119,640 116,726 108,515 105,143 99,913 95,052 97,508
Total Liabilities		 19,655 77,297 75,526 69,924 61,714 57,274 51,811 48,782 50,797
Total Current Liabilities		 6,939 22,929 20,304 16,029 17,669 18,696 15,296 16,721 17,803
Short-Term Debt		 0.17 8,846 5,476 200 1,680 2,558 2,429 5,124 4,107
Accounts Payable		 2,260 2,940 2,975 3,108 4,251 4,891 3,621 3,172 3,089
Current Deferred & Payable Income Tax Liabilities		 637 1,353 1,705 1,313 1,654 1,750 727 891 615
Other Current Liabilities		 3,763 9,365 9,255 11,408 10,083 9,497 8,520 7,535 9,987
Total Noncurrent Liabilities		 12,716 54,368 55,221 53,895 44,044 38,577 36,514 32,060 32,995
Long-Term Debt		 9,274 42,803 42,052 41,703 34,103 30,454 29,603 30,135 31,059
Noncurrent Deferred & Payable Income Tax Liabilities		 854 7,035 7,139 5,212 3,896 2,224 781 235 168
Noncurrent Employee Benefit Liabilities		 824 1,406 1,461 1,436 1,201 961 951 903 903
Other Noncurrent Operating Liabilities		 1,765 3,124 4,568 5,544 4,845 4,939 5,179 787 864
Total Equity & Noncontrolling Interests		 18,981 46,575 44,115 46,801 46,801 47,869 48,102 46,271 46,710
Total Preferred & Common Equity		 18,793 46,539 44,077 46,764 46,797 47,865 48,097 46,265 46,703
Preferred Stock		 854 14,821 15,680 15,263 14,072 13,023 11,555 11,846 11,166
Total Common Equity		 17,939 31,719 28,398 31,500 32,725 34,842 36,542 34,419 35,554
Common Stock		 733 14,761 15,566 15,080 13,803 12,628 11,087 11,305 10,657
Retained Earnings		 14,652 14,329 12,784 13,649 12,185 11,609 9,200 7,923 4,478
Treasury Stock		 -700 -513 -816 -538 -955 -756 -339 -499 -309
Other Equity Adjustments		 3,299 3,142 864 3,310 7,692 11,361 16,594 15,690 20,728
Noncontrolling Interest		 188 36 37 37 4.15 4.14 4.90 5.97 7.59

Quarterly Balance Sheets for Takeda Pharmaceutical

No quarterly balance sheets for Takeda Pharmaceutical are available.

Annual Metrics And Ratios for Takeda Pharmaceutical

This table displays calculated financial ratios and metrics derived from Takeda Pharmaceutical's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 1,723,147,386.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 1,723,147,386.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.56
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 7.13% 13.07% 63.06% -5.87% 1.66% 3.23% -7.06% 8.40% -7.33%
EBITDA Growth		 0.00% 26.02% 7.65% 55.25% 56.89% -12.35% 1.94% -27.36% 16.99% -37.88%
EBIT Growth		 0.00% 42.33% -11.62% -59.08% 545.67% -20.33% -1.05% -59.82% 54.88% -98.88%
NOPAT Growth		 0.00% 73.41% 15.55% -70.97% 620.97% -38.95% 8.19% 23.81% -63.49% -98.06%
Net Income Growth		 0.00% 69.39% -30.94% -65.93% 722.79% -44.26% 26.01% -60.07% -24.34% -232.55%
EPS Growth		 0.00% 62.42% -41.14% -79.80% 745.88% -99.50% 26.64% -60.37% -25.60% -235.61%
Operating Cash Flow Growth		 0.00% 51.51% -182.98% 311.85% 46.22% 1.20% -20.41% -35.64% 48.88% -7.17%
Free Cash Flow Firm Growth		 0.00% 0.00% -182.41% 110.01% 109.43% -49.31% -71.01% 82.42% 17.81% 262.27%
Invested Capital Growth		 0.00% 0.00% 269.23% -6.33% -10.24% -5.15% 1.56% 0.34% -3.84% -1.63%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 67.74% 71.99% 68.92% 66.89% 68.91% 68.99% 69.11% 66.54% 65.51% 65.12%
EBITDA Margin		 18.81% 22.12% 21.06% 20.06% 33.43% 28.82% 28.46% 22.25% 24.01% 16.09%
Operating Margin		 9.00% 13.66% 11.33% 3.05% 15.93% 12.91% 12.18% 5.02% 7.48% 0.14%
EBIT Margin		 8.91% 11.84% 9.25% 2.32% 15.93% 12.48% 11.96% 5.17% 7.39% 0.09%
Profit (Net Income) Margin		 6.67% 10.55% 6.44% 1.35% 11.76% 6.45% 7.87% 3.38% 2.36% -3.38%
Tax Burden Percent		 80.58% 85.96% 105.85% -72.90% 102.71% 76.07% 84.52% 273.15% 61.77% 106.86%
Interest Burden Percent		 92.89% 103.63% 65.76% -79.50% 71.90% 67.92% 77.84% 23.94% 51.71% -3,523.64%
Effective Tax Rate		 19.42% 14.04% -5.85% 0.00% -2.71% 23.93% 15.48% -173.15% 38.23% 0.00%
Return on Invested Capital (ROIC)		 0.00% 15.80% 3.89% 0.74% 5.82% 3.86% 4.25% 5.22% 1.94% 0.04%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 8.91% -0.25% 0.18% 2.11% 0.32% 1.44% -5.93% -0.75% -3.32%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 2.71% -0.19% 0.17% 1.66% 0.19% 0.79% -3.23% -0.41% -2.09%
Return on Equity (ROE)		 0.00% 18.51% 3.70% 0.91% 7.48% 4.05% 5.05% 1.99% 1.53% -2.06%
Cash Return on Invested Capital (CROIC)		 0.00% -184.20% -110.86% 7.28% 16.62% 9.14% 2.70% 4.88% 5.85% 1.68%
Operating Return on Assets (OROA)		 0.00% 5.10% 2.14% 0.59% 3.90% 3.26% 3.40% 1.42% 2.32% 0.03%
Return on Assets (ROA)		 0.00% 4.55% 1.49% 0.34% 2.88% 1.68% 2.24% 0.93% 0.74% -0.99%
Return on Common Equity (ROCE)		 0.00% 17.49% 2.80% 0.60% 4.93% 2.78% 3.60% 1.48% 1.15% -1.55%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 9.35% 2.61% 0.94% 7.27% 4.05% 4.99% 1.98% 1.56% 0.00%
Net Operating Profit after Tax (NOPAT)		 1,128 1,955 2,260 656 4,729 2,887 3,123 3,867 1,412 27
NOPAT Margin		 7.25% 11.74% 12.00% 2.14% 16.36% 9.82% 10.29% 13.71% 4.62% 0.10%
Net Nonoperating Expense Percent (NNEP)		 0.00% 6.90% 4.14% 0.56% 3.72% 3.54% 2.82% 11.14% 2.69% 3.35%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 1.85% 0.03%
Cost of Revenue to Revenue		 32.26% 28.01% 31.08% 33.11% 31.09% 31.01% 30.89% 33.46% 34.49% 34.88%
SG&A Expenses to Revenue		 35.74% 35.48% 34.22% 29.31% 27.38% 24.84% 24.76% 24.72% 24.11% 24.06%
R&D to Revenue		 18.03% 18.38% 17.56% 14.96% 14.25% 14.74% 15.73% 17.12% 15.94% 15.00%
Operating Expenses to Revenue		 58.74% 58.33% 57.59% 63.84% 52.98% 56.07% 56.93% 61.52% 58.03% 64.98%
Earnings before Interest and Taxes (EBIT)		 1,385 1,972 1,743 713 4,604 3,668 3,630 1,458 2,259 25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2,925 3,685 3,967 6,159 9,664 8,470 8,635 6,273 7,338 4,559
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.80 0.90 0.75 0.79 0.64 0.73 0.88
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.74 0.98 0.84 0.91 0.83 0.82 1.11
Price to Earnings (P/E)		 0.00 0.00 0.00 55.02 8.37 13.01 11.50 24.70 34.89 0.00
Dividend Yield		 0.00% 0.00% 2.25% 5.72% 4.58% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 1.82% 11.95% 7.69% 8.70% 4.05% 2.87% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.92 0.96 0.89 0.90 0.82 0.87 0.95
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 2.57 2.55 2.20 2.20 2.17 2.03 2.51
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 12.83 7.63 7.65 7.72 9.76 8.46 15.62
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 110.79 16.02 17.66 18.35 42.00 27.50 2,803.99
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 120.46 15.60 22.44 21.33 15.84 44.00 2,603.03
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 12.64 8.07 7.00 9.05 12.93 8.81 10.88
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 12.26 5.47 9.47 33.60 16.93 14.58 55.80
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.49 1.11 1.08 0.90 0.76 0.69 0.67 0.65 0.75
Long-Term Debt to Equity		 0.00 0.49 0.92 0.95 0.89 0.73 0.64 0.62 0.57 0.66
Financial Leverage		 0.00 0.30 0.77 0.95 0.79 0.60 0.55 0.54 0.54 0.63
Leverage Ratio		 0.00 2.04 2.48 2.69 2.60 2.41 2.26 2.14 2.07 2.07
Compound Leverage Factor		 0.00 2.11 1.63 -2.13 1.87 1.63 1.76 0.51 1.07 -72.97
Debt to Total Capital		 0.00% 32.82% 52.58% 51.86% 47.24% 43.33% 40.82% 39.97% 39.43% 42.95%
Short-Term Debt to Total Capital		 0.00% 0.00% 9.01% 5.98% 0.23% 2.03% 3.16% 3.03% 4.79% 5.02%
Long-Term Debt to Total Capital		 0.00% 32.82% 43.58% 45.89% 47.01% 41.29% 37.65% 36.94% 34.64% 37.93%
Preferred Equity to Total Capital		 0.00% 3.02% 15.09% 17.11% 17.21% 17.04% 16.10% 14.42% 15.51% 13.64%
Noncontrolling Interests to Total Capital		 0.00% 0.67% 0.04% 0.04% 0.04% 0.01% 0.01% 0.01% 0.01% 0.01%
Common Equity to Total Capital		 0.00% 63.49% 32.29% 30.99% 35.51% 39.63% 43.08% 45.60% 45.06% 43.42%
Debt to EBITDA		 0.00 2.52 13.02 7.72 4.34 4.22 3.82 5.11 4.10 7.71
Net Debt to EBITDA		 0.00 1.49 11.18 6.59 3.11 3.08 3.03 4.17 3.43 6.28
Long-Term Debt to EBITDA		 0.00 2.52 10.79 6.83 4.32 4.03 3.53 4.72 3.61 6.81
Debt to NOPAT		 0.00 4.74 22.86 72.47 8.86 12.40 10.57 8.28 21.34 1,285.49
Net Debt to NOPAT		 0.00 2.81 19.64 61.87 6.35 9.03 8.37 6.76 17.81 1,045.64
Long-Term Debt to NOPAT		 0.00 4.74 18.94 64.12 8.82 11.81 9.75 7.66 18.74 1,135.35
Altman Z-Score		 0.00 0.00 0.00 0.63 0.87 0.82 0.84 0.75 0.83 0.75
Noncontrolling Interest Sharing Ratio		 0.00% 5.49% 24.25% 33.71% 34.12% 31.38% 28.63% 25.62% 24.81% 24.74%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 1.46 1.17 1.13 1.53 1.21 0.97 1.11 1.01 1.09
Quick Ratio		 0.00 0.97 0.57 0.64 0.99 0.72 0.48 0.49 0.44 0.51
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -22,791 -64,365 6,442 13,493 6,839 1,983 3,617 4,261 1,276
Operating Cash Flow to CapEx		 238.91% 301.57% -393.87% 326.50% 532.03% 609.65% 154.44% 151.73% 304.00% 257.47%
Free Cash Flow to Firm to Interest Expense		 0.00 -75.87 -86.05 4.18 6.00 4.99 1.55 2.49 3.04 0.57
Operating Cash Flow to Interest Expense		 11.24 11.83 -3.94 4.06 4.07 6.74 5.76 3.26 5.03 2.91
Operating Cash Flow Less CapEx to Interest Expense		 6.54 7.91 -4.95 2.82 3.30 5.64 2.03 1.11 3.38 1.78
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.43 0.23 0.25 0.24 0.26 0.28 0.28 0.31 0.29
Accounts Receivable Turnover		 0.00 4.21 3.55 4.47 4.09 4.59 5.71 6.06 6.68 5.64
Inventory Turnover		 0.00 2.29 0.80 0.96 1.16 1.30 1.29 1.21 1.30 1.17
Fixed Asset Turnover		 0.00 3.30 2.21 2.47 2.22 2.25 2.35 2.18 2.33 2.14
Accounts Payable Turnover		 0.00 2.06 2.25 3.44 2.96 2.48 2.05 2.22 3.10 3.16
Days Sales Outstanding (DSO)		 0.00 86.64 102.87 81.57 89.29 79.58 63.94 60.27 54.65 64.69
Days Inventory Outstanding (DIO)		 0.00 159.67 458.16 380.63 315.89 280.88 283.76 301.92 281.72 312.20
Days Payable Outstanding (DPO)		 0.00 176.83 162.16 106.16 123.51 147.37 178.03 164.64 117.60 115.66
Cash Conversion Cycle (CCC)		 0.00 69.47 398.87 356.04 281.66 213.09 169.66 197.56 218.77 261.24
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 24,747 91,371 85,585 76,821 72,868 74,008 74,258 71,409 75,208
Invested Capital Turnover		 0.00 1.35 0.32 0.35 0.36 0.39 0.41 0.38 0.42 0.37
Increase / (Decrease) in Invested Capital		 0.00 24,747 66,625 -5,787 -8,764 -3,953 1,140 250 -2,849 -1,249
Enterprise Value (EV)		 0.00 0.00 0.00 79,009 73,765 64,780 66,624 61,249 62,108 71,210
Market Capitalization		 0.00 0.00 0.00 22,715 28,445 24,637 27,457 23,532 25,118 31,431
Book Value per Share		 $0.00 $0.00 $20.27 $18.15 $20.22 $19.02 $20.91 $21.57 $20.38 $20.95
Tangible Book Value per Share		 $0.00 $0.00 ($31.33) ($30.65) ($25.87) ($20.35) ($20.05) ($16.23) ($14.99) ($13.23)
Total Capital		 0.00 28,255 98,224 91,643 88,704 82,583 80,881 80,133 76,393 81,877
Total Debt		 0.00 9,274 51,649 47,528 41,903 35,782 33,012 32,031 30,122 35,167
Total Long-Term Debt		 0.00 9,274 42,803 42,052 41,703 34,103 30,454 29,603 26,460 31,059
Net Debt		 0.00 5,487 44,372 40,577 30,020 26,067 26,139 26,156 25,138 28,605
Capital Expenditures (CapEx)		 982 1,179 749 1,914 1,718 1,517 4,766 3,122 2,320 2,543
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 440 6,492 2,265 -39 -1,629 -2,094 1,025 1,191 1,991
Debt-free Net Working Capital (DFNWC)		 0.00 3,211 12,797 8,215 8,695 5,368 1,926 4,052 3,760 5,732
Net Working Capital (NWC)		 0.00 3,211 3,952 2,739 8,495 3,688 -633 1,623 98 1,625
Net Nonoperating Expense (NNE)		 91 199 1,046 243 1,328 991 735 2,913 690 984
Net Nonoperating Obligations (NNO)		 0.00 5,766 44,796 41,470 30,020 26,067 26,139 26,156 25,138 28,497
Total Depreciation and Amortization (D&A)		 1,539 1,714 2,225 5,446 5,059 4,802 5,005 4,814 5,079 4,533
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 2.64% 34.47% 7.38% -0.14% -5.54% -6.90% 3.63% 3.90% 7.03%
Debt-free Net Working Capital to Revenue		 0.00% 19.28% 67.94% 26.75% 30.08% 18.27% 6.35% 14.37% 12.30% 20.24%
Net Working Capital to Revenue		 0.00% 19.28% 20.98% 8.92% 29.39% 12.55% -2.09% 5.76% 0.32% 5.74%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $113.50 $28.41 $240.72 $147.14 $204.29 $0.61 $0.46 ($0.61)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B 1.72B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $112.86 $28.25 $238.96 $145.87 $201.94 $0.60 $0.45 ($0.61)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B 1.72B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B 1.72B
Normalized Net Operating Profit after Tax (NOPAT)		 1,655 2,979 2,143 2,280 4,861 3,883 4,048 1,947 2,263 2,487
Normalized NOPAT Margin		 10.64% 17.88% 11.38% 7.43% 16.82% 13.21% 13.34% 6.91% 7.41% 8.78%
Pre Tax Income Margin		 8.28% 12.27% 6.08% -1.85% 11.45% 8.48% 9.31% 1.24% 3.82% -3.16%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 6.64 6.56 2.33 0.46 2.05 2.67 2.84 1.00 1.61 0.01
NOPAT to Interest Expense		 5.40 6.51 3.02 0.43 2.10 2.10 2.44 2.66 1.01 0.01
EBIT Less CapEx to Interest Expense		 1.93 2.64 1.33 -0.78 1.28 1.57 -0.89 -1.14 -0.04 -1.12
NOPAT Less CapEx to Interest Expense		 0.70 2.59 2.02 -0.82 1.34 1.00 -1.29 0.51 -0.65 -1.12
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 122.66% 76.00% 105.83% 638.03% 75.33% 123.24% 88.13% 199.16% 279.72% -205.03%
Augmented Payout Ratio		 142.67% 86.04% 105.83% 646.46% 85.15% 156.93% 96.63% 200.78% 327.68% -238.95%

Quarterly Metrics And Ratios for Takeda Pharmaceutical

No quarterly metrics and ratios for Takeda Pharmaceutical are available.


Financials Breakdown Chart

Takeda Pharmaceutical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Takeda Pharmaceutical's financial year ends in March. Their financial year 2026 ended on March 31, 2026.

Takeda Pharmaceutical's net income appears to be on a downward trend, with a most recent value of -$956.28 million in 2026, falling from $1.04 billion in 2017. The previous period was $721.43 million in 2025. View Takeda Pharmaceutical's forecast to see where analysts expect Takeda Pharmaceutical to go next.

Takeda Pharmaceutical's total operating income in 2026 was $39.08 million, based on the following breakdown:
  • Total Gross Profit: $18.44 billion
  • Total Operating Expenses: $18.41 billion

Over the last 9 years, Takeda Pharmaceutical's total revenue changed from $15.55 billion in 2017 to $28.32 billion in 2026, a change of 82.1%.

Takeda Pharmaceutical's total liabilities were at $50.80 billion at the end of 2026, a 4.1% increase from 2025, and a 158.4% increase since 2018.

In the past 8 years, Takeda Pharmaceutical's cash and equivalents has ranged from $2.57 billion in 2025 to $8.73 billion in 2021, and is currently $3.74 billion as of their latest financial filing in 2026.

Over the last 9 years, Takeda Pharmaceutical's book value per share changed from 0.00 in 2017 to 20.95 in 2026, a change of 2,094.9%.


Related Companies

Financial statements for NYSE:TAK last updated on 6/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Are we ignoring the same signal Wall Street ignored in 1929?
In 1929, a 20-something broker named Irving Weiss shorted the market before Black Monday and made a fortune. H...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Elon’s message for America
Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...
Stansberry Research | Sponsoredtc pixel
A drilling crew just broke a record nobody expected
A drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...
Behind the Markets | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel